Indication
Cutaneous T-cell lymphoma
2 clinical trials
3 products
Clinical trial
Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)Status: Active (not recruiting), Estimated PCD: 2026-01-31
Product
SGN-35Clinical trial
A Phase I Study of Romidepsin in Combination With Parsaclisib in Relapsed and Refractory T-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
ParsaclisibProduct
Romidepsin